Literature DB >> 34546613

The effects of donor-specific antibody characteristics on cardiac allograft vasculopathy.

Maggie Wang1, Nikhil J Patel2, Xiaohai Zhang3, Evan P Kransdorf2, Babak Azarbal2, Michelle M Kittleson2, Lawrence S C Czer2, Jon A Kobashigawa2, Jignesh K Patel2.   

Abstract

BACKGROUND: Cardiac allograft vasculopathy (CAV) causes late graft dysfunction and post-transplant mortality. Currently, the effects of different donor-specific antibodies (DSA) on the severity of CAV remain unclear.
METHOD: We evaluated 526 adult heart transplant recipients at a single center between January 2010 and August 2015. Subjects were divided into those with DSA (n = 142) and those without DSA (n = 384, control). The DSA group was stratified into persistent DSA (n = 34), transient DSA (n = 105), 1:8 dilution DSA (n = 45), complement-binding (C1q) DSA (n = 36), Class I DSA (n = 37), and Class II DSA (n = 105). The primary outcome was the incidence of moderate-to-severe CAV (CAV 2/3) at 5-year follow-up.
RESULTS: Subjects with persistent DSA, 1:8 dilution DSA, and C1q DSA had higher incidence of CAV 2/3 compared the control group (17.6%, 13.3%, and 16.7% vs. 3.1%, respectively; P≤ .001). The incidence of CAV 2/3 between subjects with transient DSA and the control group was similar (2.8% vs. 3.1%; P = .888). Subjects with Class II DSA also had higher incidence of CAV 2/3 (7.6% vs. 3.1%; P = .039).
CONCLUSION: DSA that are persistent, 1:8 dilution positive, C1q positive, and Class II are associated with more severe grades of CAV. These DSA characteristics may prognosticate disease and warrant consideration for treatment.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  alloantibody; coronary artery disease; heart (allograft) function/dysfunction

Mesh:

Substances:

Year:  2021        PMID: 34546613     DOI: 10.1111/ctr.14483

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  2 in total

1.  De Novo Complement-Binding Anti-HLA Antibodies in Heart Transplanted Patients Is Associated with Severe Cardiac Allograft Vasculopathy and Poor Long-Term Survival.

Authors:  Guillaume Baudry; Matteo Pozzi; Matthieu Aubry; Elisabeth Hugon-Vallet; Raluca Mocan; Lara Chalabreysse; Philippe Portran; Jean-François Obadia; Olivier Thaunat; Nicolas Girerd; Valérie Dubois; Laurent Sebbag
Journal:  J Clin Med       Date:  2022-06-28       Impact factor: 4.964

2.  Molecular Signature of Antibody-Mediated Chronic Vasculopathy in Heart Allografts in a Novel Mouse Model.

Authors:  Hidetoshi Tsuda; Nina Dvorina; Karen S Keslar; Jessica Nevarez-Mejia; Nicole M Valenzuela; Elaine F Reed; Robert L Fairchild; William M Baldwin
Journal:  Am J Pathol       Date:  2022-04-29       Impact factor: 5.770

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.